The high‐sustained FVIII activity provided by efanesoctocog alfa can reduce the treatment burden and improve physical health and quality of life outcomes for people with hemophilia [19], potentially being an attractive option for those with hemophilia who have historically been reticent to dose prophylactically (i.e., individuals who have preferred to remain on an on‐demand regimen). Here, F8 is linked to hemophilia.